The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

DREAMM-2 demonstrates meaningful ORR with belantamab mafodotin in multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Treatment with the investigational single-agent belantamab mafodotin resulted in a 31% overall response rate with the 2.5 mg/kg regimen in patients with heavily pre-treated multiple myeloma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Victor Ambros and Gary Ruvkun share 2024 Nobel Prize in Physiology or Medicine

Victor AmbrosPhoto credit: Niklas Elmehed © Nobel Prize OutreachGary RuvkunPhoto credit: Niklas Elmehed © Nobel Prize OutreachVictor Ambros and Gary Ruvkun were jointly awarded the 2024 Nobel Prize in Physiology or Medicine from the Nobel Assembly at the Karolinska Institutet. The two scientists are being honored for their discovery of microRNA and its role in post-transcriptional gene regulation.
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account